BioStock: Idogen has reached milestone in clinical trial preparations
Idogen has optimised the GMP manufacturing process in order to maximise the treatment effect of the cell therapy IDO 8 in patients with haemophilia A. The extensive optimisation work is now completed and Idogen is thus approaching the first clinical study with IDO 8. The company is about to submit a clinical trial application to the Medical Products Agency and plans to initiate the study during the second quarter of 2022.Read the full article at biostock.se: https://www.biostock.se/en/2021/12/idogen-has-reached-milestone-in-clinical-trial-preparations/ This is a press release from